Browsing by Author "Martin, Antony P"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Evidence-based public policy making formedicines across countries: findings andimplications for the future
    (Future Medicine Ltd, 2021) Godman, Brian; Fadare, Joseph; Kwon, Hye-Young; Zampirolli Dias, Carolina; Kurdi, Amanj; Dias God ́oi, Isabella Piassi; Kibuule, Dan; Hoxha, Iris; Opanga, Sylvia; Saleem, Zikria; Bochenek, Tomasz; Markovi ́c-Pekovi ́c, Vanda; Mardare, Ileana; Kalungia, Aubrey C; Campbel, Stephen; Allocati, Eleonora; Pisana, Alice; Martin, Antony P; Meyer, Johanna C
    im:Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence ofnon-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases andother complex areas. This is difficult to sustain without reforms.Methods:Extensive narrative review ofpublished papers and contextualizing the findings to provide future guidance.Results:New models arebeing introduced to improve the managed entry of new medicines including managed entry agreements,fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have alsosuccessfully been introduced to improve the prescribing of established medicines. This includes encour-aging greater prescribing of generics and biosimilars versus originators and patented medicines in a classto conserve resources without compromising care. In addition, reducing inappropriate antibiotic utiliza-tion. Typically, multiple measures are the most effective.Conclusion:Multiple measures will be needed toattain and retain universal healthcare. Keywords:antimicrobials•biosimilars•COVID-19•demand-side measures•generics•guidelines•managedentry•oncology•orphan medicines•quality indicators•statins
  • No Thumbnail Available
    Item
    Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries:
    (Taylor & Francis, 2019) Godman, Brian; Haque, Mainul; McKimm, Judy; Bakar, Muhamad Abu; Sneddon, Jacqueline; Wale, Janney; Campbell, Stephen; Martin, Antony P; Hoxha, Iris; Abilova, Vafa; Paramadhas, Bene D Anand; Mpinda-Joseph, Pinkie; Matome, Matshediso; Pires de Lemos, Livia Lovato; Sefah, Israel; Kurdi, Amanj; Opanga, Sylvia; Jakupi, Arianit; Saleem, Zikria; Hassali, Mohamed Azmi; Kibuule, Dan; Fadare, Joseph; Bochenek, Tomasz; Rothe, Celia; Furst, Jurij; Markovic-Pekovic, Vanda; Bojanić, Ljubica; Schellack, Natalie; Meyer, Johanna C; Matsebula, Zinhle; Thi Phuong, Thuy Nguyen; Jan, Saira; Kalungia, Aubrey; Mtapuri-Zinyowera, Sekesai; Sartelli, Massimo; Hill, Ruaraidh
    Introduction: Antibiotics are indispensable to maintaining human health; however, their overuse has resulted in resistant organisms, increasing morbidity, mortality and costs. Increasing antimicrobial resistance (AMR) is a major public health threat, resulting in multiple campaigns across countries to improve appropriate antimicrobial use. This includes addressing the overuse of antimicrobials for self-limiting infections, such as upper respiratory tract infections (URTIs), particularly in lower- and middle-income countries (LMICs) where there is the greatest inappropriate use and where antibiotic utilization has increased the most in recent years. Consequently, there is a need to document current practices and successful initiatives in LMICs to improve future antimicrobial use.Methodology: Documentation of current epidemiology and management of URTIs, particularly in LMICs, as well as campaigns to improve future antimicrobial use and their influence where known.Results: Much concern remains regarding the prescribing and dispensing of antibiotics for URTIs among LMICs. This includes considerable self-purchasing, up to 100% of pharmacies in some LMICs. However, multiple activities are now ongoing to improve future use. These incorporate educational initiatives among all key stakeholder groups, as well as legislation and other activities to reduce self-purchasing as part of National Action Plans (NAPs). Further activities are still needed however. These include increased physician and pharmacist education, starting in medical and pharmacy schools; greater monitoring of prescribing and dispensing practices, including the development of pertinent quality indicators; and targeted patient information and health education campaigns. It is recognized that such activities are more challenging in LMICs given more limited resources and a lack of healthcare professionals.Conclusion: Initiatives will grow across LMICs to reduce inappropriate prescribing and dispensing of antimicrobials for URTIs as part of NAPs and other activities, and these will be monitored.
  • No Thumbnail Available
    Item
    Pharmacotherapeutic interventions for bipolar disorder type II:
    (Taylor & Francis, 2019) Godman, Brian; Grobler, Christoffel; Van-De-Lisleh, Marianne; Walei, Janney; Barbosa, Wallace Breno; Masselek, Amos; Opondo, Philip; Petrova, Guenka; Tachkov, Konstantin; Sefah, Israel; Abdulsalimo, Suhaj; Alrasheedy, Alian A.; Unnikrishnanp, Mazhuvancherry Kesavan; Garuoliene, Kristina; Bamitaler, Kayode; Kibuule, Dan; Kalemeera, Francis; Fadare, Joseph; Khan, Tanveer Ahmed; Hussain, Shahzad; Bochenek, Tomasz; Kalungia, Aubrey Chichonyi; Mwanza, James; Martin, Antony P; Hill, Ruaraidh; Barbui, Corrado
    Introduction: Appropriately managing mental disorders is a growing priority across countries in view of the impact on morbidity and mortality. This includes patients with bipolar disorders (BD). Management of BD is a concern as this is a complex disease with often misdiagnosis, which is a major issue in lower and middleincome countries (LMICs) with typically a limited number of trained personnel and resources. This needs to be addressed. Areas covered: Medicines are the cornerstone of managing patients with Bipolar II across countries including LMICs. The choice of medicines, especially antipsychotics, is important in LMICs with high rates of diabetes and HIV. However, care is currently compromised in LMICs by issues such as the stigma, cultural beliefs, a limited number of trained professionals and high patient co-payments. Expert opinion: Encouragingly, some LMICs have introduced guidelines for patients with BD; however, this is very variable. Strategies for the future include addressing the lack of national guidelines for patients with BD, improving resources for mental disorders including personnel, improving medicine availability and patients’ rights, and monitoring prescribing against agreed guidelines. A number of strategies have been identified to improve the treatment of patients with Bipolar II in LMICs, and will be followed up. KEYWORDS: Bipolar disorders; bipolar disorder type II; lower and middle-income countries; health policies; treatment; pharmaceuticals; differential diagnosis
  • No Thumbnail Available
    Item
    Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications
    (Frontiers in Pharmacology, 2021) Sefah, Israel A.; Ogunleye, Olayinka O.; Essah, Darius O.; Opanga, Sylvia A.; Butt, Nadia; Wamaitha, Annie; Guantai, Anastasia N.; Chikowe, Ibrahim; Khuluza, Felix; Kibuule, Dan; Nambahu, Lahya; Abubakar, Abdullahi R.; Sani, Ibrahim H.; Saleem, Zikria; Kalungia, Aubrey C.; Phuong, Thuy N. T.; Haque, Mainul; Islam, Salequl; Kumar, Santosh; Sneddon, Jacqueline; Wamboga, Joshua; Wale, Janney; Miljković, Nenad; Kurdi, Amanj; Martin, Antony P; Godman, Brian
    Background: Countries across Africa and Asia have introduced a variety of measures to prevent and treat COVID-19 with medicines and personal protective equipment (PPE). However, there has been considerable controversy surrounding some treatments including hydroxychloroquine where the initial hype and misinformation led to shortages, price rises and suicides. Price rises and shortages were also seen for PPE. Such activities can have catastrophic consequences especially in countries with high copayment levels. Consequently, there is a need to investigate this further. Objective: Assess changes in utilisation, prices, and shortages of pertinent medicines and PPE among African and Asian countries since the start of pandemic. Our approach: Data gathering among community pharmacists to assess changes in patterns from the beginning of March until principally the end of May 2020. In addition, suggestions on ways to reduce misinformation. Results: One hundred and thirty one pharmacists took part building on the earlier studies across Asia. There were increases in the utilisation of principally antimalarials (hydroxychloroquine) and antibiotics (azithromycin) especially in Nigeria and Ghana. There were limited changes in Namibia and Vietnam reflecting current initiatives to reduce inappropriate prescribing and dispensing of antimicrobials. Encouragingly, there was increased use of vitamins/immune boosters and PPE across the countries where documented. In addition, generally limited change in the utilisation of herbal medicines. However, shortages have resulted in appreciable price increases in some countries although moderated in others through government initiatives. Suggestions in Namibia going forward included better planning and educating patients. Conclusion: Encouraging to see increases in the utilisation of vitamins/immune boosters and PPE. However, concerns with increased utilisation of antimicrobials needs addressing alongside misinformation, unintended consequences from the pandemic and any appreciable price rises. Community pharmacists and patient organisations can play key roles in providing evidence-based advice, helping moderate prices through improved stock management, and helping address unintended consequences of the pandemic. Keywords: Africa, Asia, community pharmacists, COVID-19, medicines, protective equipment, price rises, shortages